RT @bengoldacre: If someone can explain to me why this isn't a headline story every day I'd be delighted to hear it. #AllTrials https://t.c…
RT @bengoldacre: Ew @Novartis withhold info on Aliskiren side fx, as researchers find odd discrepancies. Business as usual #AllTrials https…
RT @bengoldacre: If someone can explain to me why this isn't a headline story every day I'd be delighted to hear it. #AllTrials https://t.c…
RT @bengoldacre: Ew @Novartis withhold info on Aliskiren side fx, as researchers find odd discrepancies. Business as usual #AllTrials https…
RT @bengoldacre: Ew @Novartis withhold info on Aliskiren side fx, as researchers find odd discrepancies. Business as usual #AllTrials https…
If someone can explain to me why this isn't a headline story every day I'd be delighted to hear it. #AllTrials https://t.co/nBmLsY88ix
RT @bengoldacre: Ew @Novartis withhold info on Aliskiren side fx, as researchers find odd discrepancies. Business as usual #AllTrials https…
Ew @Novartis withhold info on Aliskiren side fx, as researchers find odd discrepancies. Business as usual #AllTrials https://t.co/d8AEtG6C4i https://t.co/QTLY65mr5M
(Cochrane) Aliskireno: efecto en la reducción de la presión arterial y perfil de efectos adversos https://t.co/QVfMD3XwUK
Aliskiren>placebo en reducir niveles de TA. Éstos ~ a IECA/ARA-II. No info de efectos adversos a largo plazo. Calidad evidencia moderada https://t.co/Lfxeh5yUuZ
(Cochrane) Eficacia antihipertensiva del aliskireno https://t.co/obEtfuewSU
Blood pressure lowering efficacy of aliskiren https://t.co/xv3JyQr36l
Blood pressure lowering efficacy of aliskiren https://t.co/K1qxCIOIBZ https://t.co/WGyck1l6e5
Do any students want to blog about the problem of safety data being withheld by a trial sponsor in this review? https://t.co/s5I8eWxf0N